VeriSign, Inc. (BMV:VRSN)

Lumos Pharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	799.5	785.7	817.6	673.8	784.8	814.9
Depreciation & Amortization	35	36.9	44.1	46.9	47.9	46.4
Loss (Gain) From Sale of Investments	-14.8	-21.1	-27.8	-7.7	-0.4	-
Stock-Based Compensation	65.1	61.1	59.7	58.6	53.4	48.2
Other Operating Activities	3.4	3.6	3.3	3.8	6.4	-9.1
Change in Accounts Payable	-	-	-	-	-	2.2
Change in Unearned Revenue	91	58.1	27	65.7	90.5	29
Change in Other Net Operating Assets	-8	-41.3	-3.7	-3.8	-12.6	-9.2
Operating Cash Flow	978.7	902.6	853.8	831.1	807.2	730.2
Operating Cash Flow Growth	12.86%	5.72%	2.73%	2.96%	10.54%	-3.14%
Capital Expenditures	-28.7	-28.1	-45.8	-27.4	-53	-43.4
Divestitures	-	-	-	-	-	20.8
Investment in Securities	173.1	314.4	-51.6	383.1	-216.2	-49.7
Investing Cash Flow	144.4	286.3	-97.4	355.7	-269.2	-72.3
Long-Term Debt Issued	-	-	-	-	741.1	-
Long-Term Debt Repaid	-	-	-	-	-750	-
Net Debt Issued (Repaid)	-6.7	-	-	-	-8.9	-
Issuance of Common Stock	11.9	12.3	12.3	12.3	12.4	12.6
Repurchase of Common Stock	-993.7	-1,234	-901.4	-1,048	-722.6	-777.5
Other Financing Activities	-	-	-0.7	-	-	-
Financing Cash Flow	-1,061	-1,222	-889.8	-1,036	-719.1	-764.9
Foreign Exchange Rate Adjustments	-0.4	-0.8	-0.1	-0.8	-0.7	-
Net Cash Flow	62.1	-33.4	-133.5	150.2	-181.8	-107
Free Cash Flow	950	874.5	808	803.7	754.2	686.8
Free Cash Flow Growth	15.77%	8.23%	0.53%	6.56%	9.81%	-3.75%
Free Cash Flow Margin	59.44%	56.15%	54.12%	56.40%	56.81%	54.29%
Free Cash Flow Per Share	9.95	8.90	7.81	7.44	6.72	5.96
Cash Interest Paid	78.7	72.8	72.8	72.8	85.6	87.4
Cash Income Tax Paid	241.3	230.5	239.7	211.7	178.4	132.7
Levered Free Cash Flow	753.86	724.91	704.71	662.48	611.43	542.97
Unlevered Free Cash Flow	801.93	771.98	751.78	709.54	663.49	599.35

Source: S&P Global Market Intelligence. Standard template. Financial Sources.